arrow
S

Sean M. Devlin

Memorial Sloan Kettering Cancer Center
H指数:58
被引数:1.9万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
HLA-A ∗01:01 Allele Is Associated With Increased Risk of Transplant-Related Mortality After MHC Matched Unmodified Allogeneic Hematopoietic Stem Cell Transplantation

HLA-A*01:01等位基因与MHC匹配的未修饰同种异基因造血干细胞移植后移植相关死亡风险增加相关

2026-09-070
OAAI
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort

异基因造血细胞移植在未达完全缓解的急性髓系白血病中的应用:当代队列的结局与预后因素

2025-11-250
OAAI
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

CD19 CAR-T疗法后大B细胞淋巴瘤患者糖皮质激素使用模式与安全性

2025-11-010
OAAI
Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

CD19靶向CAR T细胞疗法在大型B细胞淋巴瘤中的比较真实世界结果

2025-08-190
OAAI
Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patients

与年龄相关、衰老相关分泌表型及同种异基因造血细胞移植在老年患者中的结局

2025-08-190
PRE
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Barriers to Chimeric Antigen Receptor T-Cell Therapy

嵌合抗原受体T细胞疗法中的障碍

2025-05-150
PRE
Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

在接受CD19 CAR T细胞治疗的淋巴瘤患者中,从广泛的抗真菌预防转变为量身定制的抗真菌预防: 来自大型回顾性队列的结果

2025-01-010
OAAI
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

CD19嵌合抗原受体T细胞治疗后肾损伤的预测及意义

2024-11-211
OAAI
CENTRAL NERVOUS SYSTEM BRIDGING RADIOTHERAPY (CNS-BRT) ACHIEVES RAPID CYTOREDUCTION PRIOR TO CAR T-CELL THERAPY FOR AGGRESSIVE B-CELL LYMPHOMAS

中枢神经系统桥接放疗 (cns-brt) 在CAR T细胞治疗侵袭性b细胞淋巴瘤之前实现了快速的细胞减少

2024-11-110
PRE
Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

弥漫大B细胞淋巴瘤复发或难治性情况下对CAR-T疗法的肿瘤决定因素

BLOOD
IF23.1
2024-11-050
PRE
Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity
2024-10-280
OAAI
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas

CNS桥接放疗在CAR T细胞治疗侵袭性b细胞淋巴瘤之前实现了快速的细胞减少

2024-10-084
OAAI
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

淋巴瘤患者CD19-Targeted嵌合抗原受体T细胞后的后续恶性肿瘤

2024-10-013
PRE
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma
2024-09-110
PRE